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Thus far, the translation of promising results from preclinical stroke research into effective 
clinical therapy has not met with success (1). Among the numerous possible reasons for this 
failure, quality problems in some of the basic research or preclinical studies have to be 
considered. False-positive results, inflated effect sizes, and marginal reproducibility may have 
overestimated or even affected the potential of novel stroke therapeutics (2). Systematic 
reviews have found quantitative evidence that low study quality may have introduced a bias 
into preclinical stroke research (3,4,5). As opposed to many other causes of the 'translational 
roadblock', study quality is fully under the control of the researcher, and thus a prime target 
for improvement. Increasingly, funding bodies and review boards overseeing animal 
experiments are taking a proactive stance, and demand auditable measures of quality control 
in preclinical research (6). The Stroke Therapy Academic Industry Roundtable (STAIR) 
recently updated its recommendations for the evaluation of preclinical data on neuroprotective 
drugs (7) to include good laboratory practice (GLP) issues (8). 
Monitoring, auditing, and standard operating procedures (SOPs) are key elements of quality 
control in randomized clinical trials (RCTs). It has been proposed that experimental stroke 
research adapt some of the tools used in clinical stroke research. In particular, stroke 
laboratories should set up and publish their SOPs (e.g., on their institutional websites), and 
guarantee that their studies adhere to these standards (9). This is all the more important, as a 
certain portion of their experiments, evaluations, etc. are not performed by professionals, but 
rather by students in training who are unaware of these issues.  
 
A standard operating procedure (SOP) is a set of instructions with the force of a directive 
covering those features of operations that lend themselves to a definite or standardized 
procedure without loss of effectiveness. The primary purpose of an SOP in experimental 
stroke research is to guide and standardize working procedures in order to ensure data 
reliability and integrity. It is crucial that researchers, students and technicians read and follow 
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the SOPs. If this is not the case, SOPs will not only fail to achieve their goal; they will also 
engender a false sense of security. Failures are often due to technical shortcomings in the 
SOPs themselves. SOPs should be written by the user, as they must convey a clear instruction. 
The user must not only understand the instruction but also be prepared to carry it out.  
  
We in the following introduce for the first time an SOP in experimental stroke research.  
Write down what you do, do what is written down! 
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SOP for middle cerebral artery occlusion (MCAO) 
 
 
 
Title Middle cerebral artery occlusion (MCAO) in the mouse  
(intraluminal suture) 
Date Version 4: 3.4.2012 
Version History Version 1: 28.07.2009 
Version 2: 17.8.2010 
Version 3: 12.7.2011 
Name of Author Vincent Prinz, Janett König, Shengbo Ji, Ute Lindauer, Andre Rex, Ulrich 
Dirnagl 
Purpose Experimental induction of focal cerebral ischemia after occlusion of the middle 
cerebral artery  
Scope and 
Applicability 
Applies to a procedure in a standard lab equipped and certified for in vivo 
experimentation in rodents (including anesthesia with volatile anesthetics). 
Experimental procedures require approval by the relevant committees  
(in Germany: Tierversuchsgenehmigung, LAGeSo)  
Introduction Experimental focal ischemia is most commonly studied after permanent or 
transient occlusion of the middle cerebral artery (MCA) in rodents. Proximal 
MCA occlusion can be induced by an intraluminal suture (so-called filament 
model) and causes injury to cortex and deeper brain structures (striatum). Distal 
MCA occlusion (the so-called 'Brint' or 'Tamura'-models) is usually produced by 
placing a vascular clip on a pial vessel or by cautery.  Distal occlusion typically 
spares the striatum and primarily involves the neocortex. Pannecrosis develops in 
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the territory supplied by the respective artery with glial and endothelial cell death. 
If recirculation is established early (2 hrs or less) outcome is better (transient 
MCA occlusion). In some ways, the reperfused brain imitates restoration of blood 
flow after spontaneous lysis of a thromboembolic clot in humans, even though 
reperfusion after clot lysis is certainly more complex than an on-off phenomenon 
as modeled by placement and retraction of an intravascular filament. 
This SOP describes a mouse model of transient proximal MCAO (30 – 60 
minutes occlusion time). 
References Carmichael, S.T. (2005) Rodent models of focal stroke: size, mechanism, and 
purpose NeuroRx. 2(3), 396-409. Review. 
Dirnagl, U. (2006) Bench to bedside: The quest for quality in experimental stroke 
research J Cereb Blood Flow Metab 26, 1465-78. 
Dirnagl, U., Iadecola, C., Moskowitz, M.A. (1999) Pathobiology of ischaemic 
stroke: an integrated view Trends Neurosci. 22(9), 391-7.  
Engel O, Kolodziej S, Dirnagl U, Prinz V (2011) Modeling Stroke in Mice - 
Middle Cerebral Artery Occlusion with the Filament Model. J Vis 
Exp:e2423 
Shah, Z.A., Namiranian, K., Klaus, J., Kibler, K., Dore, S. (2006) Use of an 
optimized transient occlusion of the middle cerebral artery protocol for the 
mouse stroke model J Stroke Cerebrovasc Dis. 15, 133-8. 
Materials and 
Supplies  
• filament USP 4/0 or 6/0 Suprama 
• 8.0 nylon monofilament for coating with Xantopren M and Activator 
Universal Plus or commercially available filaments (e.g. Doccol)  
• Xantopren M Mucosa (Heraeus Kulzer) 
• Activator Universal Plus (Heraeus Kulzer, for Xantropren) 
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• surgical needle and thread for suture  
Instrumentation • dissecting microscope (max. x 40) 
• temperature feedback controlled heating plate 
• surgical instruments 
• forceps (Dumont Medical #5 straight tip 0,05mm x 0,02 mm) 
• surgical scissors (skin cut)  
• forceps for skin handling and suture (e.g. standard anatomical) 
• vascular spring scissors (Vannas) 
• 2 hemostats (Hartmann) 
• Micro vascular clamp (e.g. S&G B1-V) and applying forceps 
• Needle holder (Olsen-Hegar or other) 
• anesthesia system for isoflurane and nitrous oxide 
• heated recovery cage  
 
Cautions Maintain a body temperature of 36.5 +/- 0.5 °C also after reperfusion (for 2 
hours). See also Appendix below. 
Ensure proper pain relief in the perioperative and postoperative period, e.g. by 
repeated topical application of a long-acting local anaesthetic, like bupivacaine 
ointment serving as an absorption depot.  
Surgial procedures should be carried out under clean conditions. (Sterile surgical 
instruments and materials, clean gown, gloves, etc.). See also Appendix below. 
 
Personnel 
Qualifications 
In general: 
Surgeons need: 
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• general supervision and instruction, 
• the appropriate certification according to FELASA (A/B), 
• official registration. 
 
Also required in Germany: 
• official registration (Personenanzeige) 
• in Berlin: Landesamt für Gesundheit und Soziales LAGeSo,  
 
For internal use: 
• If you have questions contact Andre Rex (andre.rex@charite.de) 
• http://141.42.165.178/expneurointern/anweisungen/einweisischaemie.html  
• In the initial training phase, review our video demonstration of the MCAO 
procedure 
 
New surgeons must have passed practical qualification (see Appendix below) 
Names of SOP 
Reviewers 
Ulrich Dirnagl (ulrich.dirnagl@charite.de) 
Berlin, 02.04.2012 
Protocol 1. Mice are anaesthetized with 1.5% Isoflurane and maintained in 1.0% 
Isoflurane with 2/3 N2O and 1/3 O2 using a vaporizer.  
2. Desinfect the skin of the ventral neck with an alcohol based skin disinfectant 
(e.g. Octenisept).  
3. A midline neck incision is made and the soft tissues are pulled apart. 
4. The left common carotid artery (LCCA) is carefully dissected free from the 
surrounding nerves (without harming the vagus nerve) and a ligature is made 
using 6.0/7.0 string. 
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5. Then the left external carotid artery (LECA) is separated and a loose thread 
(6.0/7.0) is looped around it above the occipital artery bifurcation and 
secured externally with a pair of hemostats. 
6. Next, the left internal carotid artery (LICA) is isolated and a knot is prepared 
with a 6.0 filament. 
7. After obtaining good view of the left internal cerebral artery (LICA) and the 
left pterygopalatine artery (LPA), the LICA is clipped. 
8. A small hole is cut in the LCCA before it bifurcates to the LECA and the 
LICA. A monofilament made of 8.0 nylon coated with silicon hardener 
mixture (see below) is then introduced into the artery.  
9. The clipped arteries are opened while the filament is inserted about 9 mm 
into the LICA to occlude LMCA.  
10. The third knot on the LICA is closed to fix the filament in position and the 
thread around the LECA is removed. 
11. For pain relief, Bupivacaine gel is topically applied in the wound, and the 
wound is temporally closed with a Michel suture clip or with an adaptive 
suture. The mice receive saline 0.5 ml subcutaneously as volume 
replenishment.   
12.  The mice are allowed to recover in the heated recovery cage for the duration 
of the occlusion. 
13. After X min/hours occlusion, the mice are re-anaesthetized and the third knot 
is opened and the filament withdrawn (if reperfusion is intended)  
14. All animals receive second volume replenishment as described above. 
15. The remaining sutures are cut and the skin is adapted with a surgical suture 
16. The body temperature of the mice during surgery is maintained at 36.5°C ± 
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0.5°C using a heating plate. 
17. I think it is very, very important to release the ligature on the LECA.. 
 
For sham operations the filament is inserted to occlude LMCA and withdrawn 
immediately to allow instant reperfusion (8.). The subsequent operation is 
identical to the animals undergoing cerebral ischemia (9.-14.).  
 
A video is available which demonstrates the above described procedure. (see 
references) 
 
Monofilament construction: 
• 8.0 nylon filament is cut into pieces of 11 mm length under the 
microscope 
• the filament tip must be coated over a distance of 8 mm completely and 
evenly with a hardener mixture of Xantopren M Mucosa and Activator 
Universal Plus 
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Appendix to SOP: 
1. Entry qualification experiment for mouse MCAO surgeons 
2. Randomized selection of animals from cage and concealment of treatment allocation 
2 a. Pharmacological study 
2 b. Genetically manipulated animals 
3. Temperature control 
4. Outcome assessment 
5. Physiological parameters 
6. Quasi-sterile surgery 
 
1. Entry qualification experiment for mouse MCAO surgeons: 
New surgeons need to demonstrate in a series of experiments that they perform the 
MCAO-operation within 15 minutes. Reproducibility is verified by induction of a certain 
infarct volume within a standard deviation of 40%. Mortality must not exceed 10% within 
24 hours.  
 
 
2. Randomized selection of animals from cage and concealment of treatment 
allocation 
2 a. Pharmacological study: 
Animals in cage are marked with bar/dot code at the beginning of the procedure. 
Computer program (random number generator) selects animal, and assigns it to concealed 
treatment arm ('A', 'B', etc.). 
Stock solution or pharmaceutical ready for application is prepared by assistant and 
randomly assigned code ('A', 'B', etc.). 
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2 b. Genetically manipulated animals: 
Animals in both cages (e.g. knockout / wildtype) are marked with bar/dot code at the 
beginning of the procedure. Computer program (random number generator) selects animal 
and assigns it to concealed experimental arm ('A', 'B', etc.). Blinded intervention whenever 
possible.  
 
3. Temperature control: 
The body temperature of mice during surgery is maintained at 36.5°C ± 0.5°C using a 
temperature controlled heating plate. Maintain a body temperature of 36.5 +/- 0.5 °C also 
after reperfusion (for 2 hours) using a heated recovery box. 
 
4. Outcome assessment 
Infarct volume should be evaluated blinded. Functional outcome (more than Bederson 
Score!) should be assessed as well. Mortality and exclusion of animals have to be 
reported, including specific causes for exclusion.  
 
Exclusion criteria: 
- no stroke, 
- Problems during induction of MCAo (excessive bleeding, prolonged operation time ≥ 
15 min, thread placement). 
 
CAVE: 
Especially in genetically manipulated animals, be aware of vascular alterations, which 
might directly affect stroke outcome 
 
5. Physiological parameters: 
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MABP, HR, blood gases, CBF should be measured in selected animals. 
 
 
6. Quasi-sterile surgery 
Prior to surgery, the surgeon has to scrub his hands. It is advisable to wear clean gown, 
and non-sterile gloves at all times the animal is being handled. The surgeon has to wear a 
clean gown, cap and mask during surgery. Surgical gloves ought to be worn. If gloves 
cannot be used, a surgical hand scrub from tips to elbows must precede every operation.  
The necessary components of aseptic techniques in rodents include also sterile 
instruments, and separate surgical and animal prep areas. The use of glass bead sterilizer 
for re-sterilization of instruments during for repetitive procedures is recommended. 
 
• All instruments used must be sterilized prior to each group of surgeries. 
• Instruments must be kept on sterile non-porous drapes during use. 
• Separate instruments should be used for skin and tissue handling. 
• Instruments must be cleaned of blood and debris by brushing or wiping with 
sterile water or saline and sterile gauze sponges between surgeries. (Best: 
distilled water) 
• If contamination has occurred, instruments must be placed in 70% ethanol or 
a glass bead sterilizer for the appropriate period of time for the method used 
to be effective (or the instrument pack replaced by a new sterile instrument 
pack) between animals. 
• If 70% ethanol is used, instruments must be rinsed with sterile water or saline 
before being used on the next animal. 
• Surgical gloves and blades should be changed after contamination.  
• Following surgery all instruments must be thoroughly cleaned and rinsed. 
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7. Postoperative care: 
 
After surgery the animals must be weighted and checked daily for signs of discomfort. 
The mice could show some weight loss post-surgery. To avoid dehydration the mice 
receive daily s.c. injections as volume replenishment. The mice receive mashed food in a 
petri-dish placed on the floor to encourage eating. The food is replaced daily for seven 
days. 
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